This article contains findings obtained from research on animals:
- The results from animal research studies should not be directly applied to humans and the results may not generalise to the human population.
- There may be significant differences between species in terms of physiology, physiology, and pharmacology, as well as differences in the way diseases and treatments are modelled in animals.
- Any conclusions drawn from animal research should be considered with caution and in the context of other types of research studies such as observational studies, clinical trials, and reviews of the literature.
Insights & Discussion
A traditional Chinese prescription, Yu Ping Feng San, significantly mitigates symptoms in cases of asthma recurrence, outperforming commonly prescribed asthma medications.
In the research, an optimized mouse model was employed, which was induced with asthma recurrence by house dust mites. This model exhibited classic asthma responses, such as augmented airways hyperresponsiveness, increased serum IgE, and elevated pulmonary type 2 cytokines levels among others. Then, YPFS was applied during the remission phase preceding a second symptomatic phase. The researchers observed significant improvements in the asthmatic pathological features, and compared its effectiveness to three different types of standard clinical medications: dexamethasone, montelukast, and salbutamol, which were given during the recurrence phase.
The research results revealed that the application of YPFS during the remission phase remarkably alleviated the asthma relapses induced by house dust mites. This was achieved by restoring the deficiency of desmoglein 1 (a type of protein) and decreasing thymic stromal lymphopoietin (a type of cytokine) overexpression, which are believed to be key contributors to chronic asthma relapse. Not only was the fundamental role of desmoglein 1 in asthma pathogenesis demonstrated, it also gave rise to a new and potent strategy for chronic asthma treatment.
Discover Related Insights
Jia Wei Yu Ping Feng San, a traditional Chinese medicine, alleviates allergic asthma by reducing airway inflammation, mediated by suppressing group 2 innate lymphoid cells.
2021 Frontiers in Pharmacology Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma Xue L, Li C, Ge G, Zhang S, Tian L, Wang Y, et al.
Clinical Study Yu Ping Feng San
In this study, a model of allergic asthma was established by sensitizing and challenging female C57BL/6 mice with Ovalbumin (OVA). Following this, the assessment of airway hyperresponsiveness was done using direct airway resistance analysis. Levels of inflammation were examined in bronchoalveolar lavage fluid (BALF), and lung tissue sections were analyzed through HE and PAS staining, studying mucus hypersecretion and inflammatory cell infiltration. The number and proportion of ILC2s, their related transcription factors (GATA3, IRF4), and type 2 cytokines were also measured from lung tissue samples. Moreover, the ILC2s were extracted from mouse lungs followed by evaluation of ILC2s-related cytokines, and transcription factors GATA3 and IRF4 after IL33-induced activation of ILC2s.
The results showed that JWYPFS treatment significantly mitigated airway resistance and decreased inflammatory cells such as eosinophils in these mice. It also hindered mucus production and type 2 cytokines. Importantly, JWYPFS dramatically decreased the number and proportion of ILC2s, and the mRNA levels of their related transcription factors - GATA3, and IRF4. This research indicates that JWYPFS could be an effective agent in treating allergic asthma by alleviating ILC2s-mediated airway inflammation.
The use of Yu Ping Feng San for pediatric allergic rhinitis appears relatively safe compared to Western medical therapy yet its routine use remains unsupported.
2021 Medicine Yu ping feng san for pediatric allergic rhinitis Liao Y, Zhong J, Liu S, Dai M, Liu Y, Li X, et al.
Systematic Review Children's Health Hay Fever Yu Ping Feng San
The study undertakes a systematic search across multiple databases, including PubMed, the Excerpta Medical Database, Cochrane library and more, for randomized controlled trials (RCTs) concerning the use of YPFS for pediatric allergic rhinitis. Extracted results were subjected to stringent bias-risk analysis based on the Cochrane Handbook. A meta-analysis was then implemented using RevMan 5.3 software, and the Grading of Recommendations Assessment, Development and Evaluation methodology was applied to check the quality of evidence for every outcome.
The study pooled 10 RCTs covering 1,069 participants aged between 3-15 years for initial inclusion. After certain exclusions, it was determined from the remaining eight RCTs that the overall efficacy did not show any notable advantage for the test group. In addition, inspections into variation of serum immunoglobulin levels showed no statistical significance. However, the safety of YPFS displayed better results, demonstrating a relatively safer approach with lower recurrence rates compared to Western medical therapy.
Yu Ping Feng San, a Chinese herbal medicine, combined with pharmacotherapy could be effective for treating allergic rhinitis in adults.
2017 BMC Complementary Medicine and Therapies Potential effectiveness of Chinese herbal medicine Yu ping feng san for adult allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials Luo Q, Zhang CS, Yang L, Zhang AL, Guo X, Xue CC, et al.
Systematic Review Hay Fever Yu Ping Feng San
The paper evaluates Chinese herbal medicine, YPFS, for treating allergic rhinitis in adults by conducting a meta-analysis and subgroup meta-analyses of several randomized controlled trials (RCTs). Seven databases were searched from their inceptions to September 2017 where RCTs evaluating YPFS for adult allergic rhinitis were included. The Cochrane risk of bias tool was used to assess the methodological quality of these studies and meta-analysis and subgroup meta-analyses were conducted to evaluate the effectiveness of YPFS.
Based on the results, YPFS when used in combination with pharmacotherapy seemed to be more effective than using pharmacotherapy alone for treating allergic rhinitis. The paper highlighted an alleviation of four individual nasal symptom scores post YPFS combination treatment; these being itchy nose, sneezing, blocked nose, and runny nose. Furthermore, it was found that the YPFS combination treatment was more beneficial when it was used for more than three weeks. The paper also mentions that YPFS was safe and well-tolerated for treating adult allergic rhinitis. However, it did not seem to be superior to the second-generation antihistamine.